Key Highlights
- Click Therapeutics acquires Better Therapeutics’ assets, including AspyreRx.
- Advances pipeline in obesity, diabetes, and cardiometabolic diseases.
- Integration to enhance development of digital therapies for chronic weight management.
- Focus on innovative features like smart titration and personalized side effect management.
- Combination of digital and drug therapies for improved patient outcomes.
Source: Business Wire
Notable Quotes
- “There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” – Rich DeNunzio, Chief Commercial Officer at Click Therapeutics
- “Click can immediately strengthen AspyreRx by combining the latest engagement technology from our platform with Better’s therapeutic core,” – Han Chiu, Chief Technology Officer at Click Therapeutics
SoHC's Take
Click Therapeutics’ acquisition of Better Therapeutics’ assets marks a significant advancement in the field of digital therapeutics, particularly for obesity and cardiometabolic diseases. By integrating clinically-validated digital therapies like AspyreRx with their AI-enabled platform, Click is positioned to deliver personalized and effective treatment options. This strategic move not only accelerates their development timelines but also strengthens their competitive edge in a rapidly growing market. The focus on smart titration and personalized side effect management highlights Click’s commitment to improving patient outcomes and providing innovative solutions in digital health.
